Parkin and mitochondrial quality control: Toward assembling the puzzle

Trends in Cell Biology

Volumn 24, Issue 6, 2014, Pages 332-341

  Winklhofer, Konstanze F ^a,b  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b Germany 3 Munich Cluster for Systems Neurology   (Germany)

Author keywords

E3 ligases; Mitochondria; Mitophagy; Parkin; PINK1; Ubiquitin

Indexed keywords

PARKIN; PINK1 PROTEIN; PROTEASOME; PROTEIN; RING FINGER PROTEIN; UBIQUITIN; UNCLASSIFIED DRUG; UBIQUITIN PROTEIN LIGASE;

CELL DEATH; CELL STRESS; CELL VIABILITY; DOPAMINERGIC NERVE CELL; ENZYME ACTIVITY; ENZYME DEGRADATION; ENZYME STRUCTURE; HUMAN; INNATE IMMUNITY; MITOCHONDRION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DOMAIN; QUALITY CONTROL; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; CHEMISTRY; METABOLISM; PHYSIOLOGY;

ANIMALS; HUMANS; IMMUNITY, INNATE; MITOCHONDRIA; PROTEASOME ENDOPEPTIDASE COMPLEX; UBIQUITIN-PROTEIN LIGASES;

EID: 84901471156     PISSN: 09628924     EISSN: 18793088     Source Type: Journal    
DOI: 10.1016/j.tcb.2014.01.001     Document Type: Review

References (116)

1. Kitada T., et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 1998, 392:605-608.
2. Nuytemans K., et al. Genetic etiology of Parkinson disease associated with mutations in the SNCA, PARK2, PINK1, PARK7, and LRRK2 genes: a mutation update. Hum. Mutat. 2010, 31:763-780.
3. Cruts M., et al. Locus-specific mutation databases for neurodegenerative brain diseases. Hum. Mutat. 2012, 33:1340-1344.
4. Dawson T.M., Dawson V.L. The role of parkin in familial and sporadic Parkinson's disease. Mov. Disord. 2010, 25(Suppl. 1):S32-S39.
5. Exner N., et al. Mitochondrial dysfunction in Parkinson's disease: molecular mechanisms and pathophysiological consequences. EMBO J. 2012, 31:3038-3062.
6. Trempe J.F., Fon E.A. Structure and function of parkin, PINK1, and DJ-1, the Three Musketeers of neuroprotection. Front. Neurol. 2013, 4:38.
7. Corti O., et al. What genetics tells us about the causes and mechanisms of Parkinson's disease. Physiol. Rev. 2011, 91:1161-1218.
8. Trempe J.F., et al. Structure of parkin reveals mechanisms for ubiquitin ligase activation. Science 2013, 340:1451-1455.
9. Riley B.E., et al. Structure and function of parkin E3 ubiquitin ligase reveals aspects of RING and HECT ligases. Nat. Commun. 2013, 4:1982.
10. Wauer T., Komander D. Structure of the human parkin ligase domain in an autoinhibited state. EMBO J. 2013, 32:2099-2112.
11. Spratt D.E., et al. A molecular explanation for the recessive nature of parkin-linked Parkinson's disease. Nat. Commun. 2013, 4:1983.
12. Wenzel D.M., Klevit R.E. Following Ariadne's thread: a new perspective on RBR ubiquitin ligases. BMC Biol. 2012, 10:24.
13. Dove K.K., Klevit R.E. Structural biology: parkin's serpentine shape revealed in the Year of the Snake. Curr. Biol. 2013, 23:R691-R693.
14. Chaugule V.K., et al. Autoregulation of parkin activity through its ubiquitin-like domain. EMBO J. 2011, 30:2853-2867.
15. Chew K.C., et al. Parkin mediates apparent e2-independent monoubiquitination in vitro and contains an intrinsic activity that catalyzes polyubiquitination. PLoS ONE 2011, 6:e19720.
16. 2+-binding domain in the autosomal recessive juvenile Parkinson-related E3 ligase parkin. J. Biol. Chem. 2009, 284:14978-14986.
17. Duda D.M., et al. Structure of HHARI, a RING-IBR-RING ubiquitin ligase: autoinhibition of an Ariadne-family E3 and insights into ligation mechanism. Structure 2013, 21:1030-1041.
18. Smit J.J., et al. The E3 ligase HOIP specifies linear ubiquitin chain assembly through its RING-IBR-RING domain and the unique LDD extension. EMBO J. 2012, 31:3833-3844.
19. Stieglitz B., et al. LUBAC synthesizes linear ubiquitin chains via a thioester intermediate. EMBO Rep. 2012, 13:840-846.
20. Sarraf S.A., et al. Landscape of the PARKIN-dependent ubiquitylome in response to mitochondrial depolarization. Nature 2013, 496:372-376.
21. Muller-Rischart A.K., et al. The E3 ligase parkin maintains mitochondrial integrity by increasing linear ubiquitination of NEMO. Mol. Cell 2013, 49:908-921.
22. Kim K.Y., et al. Parkin is a lipid-responsive regulator of fat uptake in mice and mutant human cells. J. Clin. Invest. 2011, 121:3701-3712.
23. Cha G.H., et al. Parkin negatively regulates JNK pathway in the dopaminergic neurons of Drosophila. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:10345-10350.
24. Darios F., et al. Parkin prevents mitochondrial swelling and cytochrome c release in mitochondria-dependent cell death. Hum. Mol. Genet. 2003, 12:517-526.
25. Shimura H., et al. Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat. Genet. 2000, 25:302-305.
26. Burchell L., et al. Small, N-terminal tags activate parkin E3 ubiquitin ligase activity by disrupting its autoinhibited conformation. PLoS ONE 2012, 7:e34748.
27. Yang Y.X., et al. Induction of parkin expression in the presence of oxidative stress. Eur. J. Neurosci. 2006, 24:1366-1372.
28. Sun X., et al. ATF4 protects against neuronal death in cellular Parkinson's disease models by maintaining levels of parkin. J. Neurosci. 2013, 33:2398-2407.
29. Klinkenberg M., et al. Restriction of trophic factors and nutrients induces PARKIN expression. Neurogenetics 2012, 13:9-21.
30. Bouman L., et al. Parkin is transcriptionally regulated by ATF4: evidence for an interconnection between mitochondrial stress and ER stress. Cell Death Differ. 2011, 18:769-782.
31. Zhang C., et al. Parkin, a p53 target gene, mediates the role of p53 in glucose metabolism and the Warburg effect. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:16259-16264.
32. Henn I.H., et al. Parkin mediates neuroprotection through activation of IkappaB kinase/nuclear factor-kappaB signaling. J. Neurosci. 2007, 27:1868-1878.
33. Higashi Y., et al. Parkin attenuates manganese-induced dopaminergic cell death. J. Neurochem. 2004, 89:1490-1497.
34. Imai Y., et al. Parkin suppresses unfolded protein stress-induced cell death through its E3 ubiquitin-protein ligase activity. J. Biol. Chem. 2000, 275:35661-35664.
35. Tan E.K., et al. Impaired transcriptional upregulation of parkin promoter variant under oxidative stress and proteasomal inhibition: clinical association. Hum. Genet. 2005, 118:484-488.
36. Clark I.E., et al. Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin. Nature 2006, 441:1162-1166.
37. Greene J.C., et al. Mitochondrial pathology and apoptotic muscle degeneration in Drosophila parkin mutants. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:4078-4083.
38. Park J., et al. Mitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin. Nature 2006, 441:1157-1161.
39. Yang Y., et al. Mitochondrial pathology and muscle and dopaminergic neuron degeneration caused by inactivation of Drosophila Pink1 is rescued by parkin. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:10793-10798.
40. Narendra D., et al. Parkin is recruited selectively to impaired mitochondria and promotes their autophagy. J. Cell Biol. 2008, 183:795-803.
41. Narendra D.P., et al. PINK1 is selectively stabilized on impaired mitochondria to activate parkin. PLoS Biol. 2010, 8:e1000298.
42. Vives-Bauza C., et al. PINK1/parkin direct mitochondria to autophagy. Autophagy 2010, 6:315-316.
43. Geisler S., et al. PINK1/parkin-mediated mitophagy is dependent on VDAC1 and p62/SQSTM1. Nat. Cell Biol. 2010, 12:119-131.
44. Matsuda N., et al. PINK1 stabilized by mitochondrial depolarization recruits parkin to damaged mitochondria and activates latent parkin for mitophagy. J. Cell Biol. 2010, 189:211-221.
45. Lin W., Kang U.J. Characterization of PINK1 processing, stability, and subcellular localization. J. Neurochem. 2008, 106:464-474.
46. Jin S.M., et al. Mitochondrial membrane potential regulates PINK1 import and proteolytic destabilization by PARL. J. Cell Biol. 2010, 191:933-942.
47. Meissner C., et al. The mitochondrial intramembrane protease PARL cleaves human Pink1 to regulate Pink1 trafficking. J. Neurochem. 2011, 117:856-867.
48. Greene A.W., et al. Mitochondrial processing peptidase regulates PINK1 processing, import and parkin recruitment. EMBO Rep. 2012, 13:378-385.
49. Whitworth A.J., et al. Rhomboid-7 and HtrA2/Omi act in a common pathway with the Parkinson's disease factors Pink1 and parkin. Dis. Model Mech. 2008, 1:168-174. discussion 173.
50. Deas E., et al. PINK1 cleavage at position A103 by the mitochondrial protease PARL. Hum. Mol. Genet. 2011, 20:867-879.
51. Shi G., et al. Functional alteration of PARL contributes to mitochondrial dysregulation in Parkinson's disease. Hum. Mol. Genet. 2011, 20:1966-1974.
52. Yamano K., Youle R.J. PINK1 is degraded through the N-end rule pathway. Autophagy 2013, 9:1758-1769.
53. Lazarou M., et al. Role of PINK1 binding to the TOM complex and alternate intracellular membranes in recruitment and activation of the E3 ligase parkin. Dev. Cell 2012, 22:320-333.
54. Becker D., et al. Pink1 kinase and its membrane potential (deltapsi)-dependent cleavage product both localize to outer mitochondrial membrane by unique targeting mode. J. Biol. Chem. 2012, 287:22969-22987.
55. Gomez-Sanchez R., et al. Mitochondrial impairment increases FL-PINK1 levels by calcium-dependent gene expression. Neurobiol. Dis. 2014, 62:426-440.
56. Lazarou M., et al. PINK1 drives parkin self-association and HECT-like E3 activity upstream of mitochondrial binding. J. Cell Biol. 2013, 200:163-172.
57. Hasson S.A., et al. High-content genome-wide RNAi screens identify regulators of parkin upstream of mitophagy. Nature 2013, 504:291-295.
58. McCoy M.K., et al. Hexokinase activity is required for recruitment of parkin to depolarized mitochondria. Hum. Mol. Genet. 2014, 23:145-156.
59. Tanaka A., et al. Proteasome and p97 mediate mitophagy and degradation of mitofusins induced by parkin. J. Cell Biol. 2010, 191:1367-1380.
60. Wang X., et al. PINK1 and parkin target Miro for phosphorylation and degradation to arrest mitochondrial motility. Cell 2011, 147:893-906.
61. Liu S., et al. Parkinson's disease-associated kinase PINK1 regulates Miro protein level and axonal transport of mitochondria. PLoS Genet. 2012, 8:e1002537.
62. Gegg M.E., et al. Mitofusin 1 and mitofusin 2 are ubiquitinated in a PINK1/parkin-dependent manner upon induction of mitophagy. Hum. Mol. Genet. 2010, 19:4861-4870.
63. Chan N.C., et al. Broad activation of the ubiquitin-proteasome system by parkin is critical for mitophagy. Hum. Mol. Genet. 2011, 20:1726-1737.
64. Ziviani E., et al. Drosophila parkin requires PINK1 for mitochondrial translocation and ubiquitinates mitofusin. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:5018-5023.
65. Poole A.C., et al. The mitochondrial fusion-promoting factor mitofusin is a substrate of the PINK1/parkin pathway. PLoS ONE 2010, 5:e10054.
66. Rakovic A., et al. Mutations in PINK1 and parkin impair ubiquitination of mitofusins in human fibroblasts. PLoS ONE 2011, 6:e16746.
67. Yoshii S.R., et al. Parkin mediates proteasome-dependent protein degradation and rupture of the outer mitochondrial membrane. J. Biol. Chem. 2011, 286:19630-19640.
68. Kondapalli C., et al. PINK1 is activated by mitochondrial membrane potential depolarization and stimulates parkin E3 ligase activity by phosphorylating serine 65. Open Biol. 2012, 2:120080.
69. Shiba-Fukushima K., et al. PINK1-mediated phosphorylation of the parkin ubiquitin-like domain primes mitochondrial translocation of parkin and regulates mitophagy. Sci. Rep. 2012, 2:1002.
70. Iguchi M., et al. Parkin-catalyzed ubiquitin-ester transfer is triggered by PINK1-dependent phosphorylation. J. Biol. Chem. 2013, 288:22019-22032.
71. Thomas K.J., et al. DJ-1 acts in parallel to the PINK1/parkin pathway to control mitochondrial function and autophagy. Hum. Mol. Genet. 2011, 20:40-50.
72. Vives-Bauza C., et al. PINK1-dependent recruitment of parkin to mitochondria in mitophagy. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:378-383.
73. Okatsu K., et al. PINK1 autophosphorylation upon membrane potential dissipation is essential for parkin recruitment to damaged mitochondria. Nat. Commun. 2012, 3:1016.
74. Chen Y., Dorn G.W. PINK1-phosphorylated mitofusin 2 is a parkin receptor for culling damaged mitochondria. Science 2013, 340:471-475.
75. Burchell V.S., et al. The Parkinson's disease-linked proteins Fbxo7 and parkin interact to mediate mitophagy. Nat. Neurosci. 2013, 16:1257-1265.
76. Kim N.C., et al. VCP is essential for mitochondrial quality control by PINK1/parkin and this function is impaired by VCP mutations. Neuron 2013, 78:65-80.
77. Zhang L., et al. TRAP1 rescues PINK1 loss-of-function phenotypes. Hum. Mol. Genet. 2013, 22:2829-2841.
78. Costa A.C., et al. Drosophila Trap1 protects against mitochondrial dysfunction in a PINK1/parkin model of Parkinson's disease. Cell Death Dis. 2013, 4:e467.
79. Klein P., et al. Ret rescues mitochondrial morphology and muscle degeneration of Drosophila Pink1 mutants. EMBO J. 2014, 10.1002/embj.201284290.
80. Kim S.J., et al. Hepatitis C virus induces the mitochondrial translocation of parkin and subsequent mitophagy. PLoS Pathog. 2013, 9:e1003285.
81. Jin S.M., Youle R.J. The accumulation of misfolded proteins in the mitochondrial matrix is sensed by PINK1 to induce PARK2/parkin-mediated mitophagy of polarized mitochondria. Autophagy 2013, 9:1750-1757.
82. Suen D.F., et al. Parkin overexpression selects against a deleterious mtDNA mutation in heteroplasmic cybrid cells. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:11835-11840.
83. Hamalainen R.H., et al. Tissue- and cell-type-specific manifestations of heteroplasmic mtDNA 3243A>G mutation in human induced pluripotent stem cell-derived disease model. Proc. Natl. Acad. Sci. U.S.A. 2013, 110:E3622-E3630.
84. Gilkerson R.W., et al. Mitochondrial autophagy in cells with mtDNA mutations results from synergistic loss of transmembrane potential and mTORC1 inhibition. Hum. Mol. Genet. 2012, 21:978-990.
85. Vincow E.S., et al. The PINK1-parkin pathway promotes both mitophagy and selective respiratory chain turnover in vivo. Proc. Natl. Acad. Sci. U.S.A. 2013, 110:6400-6405.
86. Soubannier V., et al. A vesicular transport pathway shuttles cargo from mitochondria to lysosomes. Curr. Biol. 2012, 22:135-141.
87. Sterky F.H., et al. Impaired mitochondrial transport and parkin-independent degeneration of respiratory chain-deficient dopamine neurons in vivo. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:12937-12942.
88. Lee Y., et al. Parthanatos mediates AIMP2-activated age-dependent dopaminergic neuronal loss. Nat. Neurosci. 2013, 16:1392-1400.
89. Shin J.H., et al. PARIS (ZNF746) repression of PGC-1alpha contributes to neurodegeneration in Parkinson's disease. Cell 2011, 144:689-702.
90. Ekholm-Reed S., et al. Parkin-dependent degradation of the F-box protein Fbw7beta promotes neuronal survival in response to oxidative stress by stabilizing Mcl-1. Mol. Cell. Biol. 2013, 33:3627-3643.
91. Sha D., et al. Phosphorylation of parkin by Parkinson disease-linked kinase PINK1 activates parkin E3 ligase function and NF-kappaB signaling. Hum. Mol. Genet. 2010, 19:352-363.
92. Makris C., et al. Female mice heterozygous for IKK gamma/NEMO deficiencies develop a dermatopathy similar to the human X-linked disorder incontinentia pigmenti. Mol. Cell 2000, 5:969-979.
93. Schmidt-Supprian M., et al. NEMO/IKK gamma-deficient mice model incontinentia pigmenti. Mol. Cell 2000, 5:981-992.
94. Rieser E., et al. Linear ubiquitination: a newly discovered regulator of cell signalling. Trends Biochem. Sci. 2013, 38:94-102.
95. Pilsl A., Winklhofer K.F. Parkin, PINK1 and mitochondrial integrity: emerging concepts of mitochondrial dysfunction in Parkinson's disease. Acta Neuropathol. 2012, 123:173-188.
96. Lutz A.K., et al. Loss of parkin or PINK1 function increases Drp1-dependent mitochondrial fragmentation. J. Biol. Chem. 2009, 284:22938-22951.
97. Berger A.K., et al. Parkin selectively alters the intrinsic threshold for mitochondrial cytochrome c release. Hum. Mol. Genet. 2009, 18:4317-4328.
98. Belenguer P., Pellegrini L. The dynamin GTPase OPA1: more than mitochondria?. Biochim. Biophys. Acta 2013, 1833:176-183.
99. Martinou J.C., Youle R.J. Mitochondria in apoptosis: Bcl-2 family members and mitochondrial dynamics. Dev. Cell 2011, 21:92-101.
100. Ramonet D., et al. Optic atrophy 1 mediates mitochondria remodeling and dopaminergic neurodegeneration linked to complex I deficiency. Cell Death Differ. 2013, 20:77-85.
101. Jiang H., et al. Parkin protects human dopaminergic neuroblastoma cells against dopamine-induced apoptosis. Hum. Mol. Genet. 2004, 13:1745-1754.
102. Ren Y., et al. Parkin protects dopaminergic neurons against microtubule-depolymerizing toxins by attenuating microtubule-associated protein kinase activation. J. Biol. Chem. 2009, 284:4009-4017.
103. Hwang S., et al. Parkin suppresses c-Jun N-terminal kinase-induced cell death via transcriptional regulation in Drosophila. Mol. Cells 2010, 29:575-580.
104. Duplan E., et al. ER-stress-associated functional link between parkin and DJ-1 via a transcriptional cascade involving the tumor suppressor p53 and the spliced X-box binding protein XBP-1. J. Cell Sci. 2013, 126:2124-2133.
105. da Costa C.A., et al. Transcriptional repression of p53 by parkin and impairment by mutations associated with autosomal recessive juvenile Parkinson's disease. Nat. Cell Biol. 2009, 11:1370-1375.
106. Johnson B.N., et al. The ubiquitin E3 ligase parkin regulates the proapoptotic function of Bax. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:6283-6288.
107. Mira M.T., et al. Susceptibility to leprosy is associated with PARK2 and PACRG. Nature 2004, 427:636-640.
108. Ali S., et al. PARK2/PACRG polymorphisms and susceptibility to typhoid and paratyphoid fever. Clin. Exp. Immunol. 2006, 144:425-431.
109. Chopra R., et al. Mapping of PARK2 and PACRG overlapping regulatory region reveals LD structure and functional variants in association with leprosy in unrelated Indian population groups. PLoS Genet. 2013, 9:e1003578.
110. Manzanillo P.S., et al. The ubiquitin ligase parkin mediates resistance to intracellular pathogens. Nature 2013, 501:512-516.
111. de Leseleuc L., et al. PARK2 mediates interleukin 6 and monocyte chemoattractant protein 1 production by human macrophages. PLoS Negl. Trop. Dis. 2013, 7:e2015.
112. Itier J.M., et al. Parkin gene inactivation alters behaviour and dopamine neurotransmission in the mouse. Hum. Mol. Genet. 2003, 12:2277-2291.
113. Goldberg M.S., et al. Parkin-deficient mice exhibit nigrostriatal deficits but not loss of dopaminergic neurons. J. Biol. Chem. 2003, 278:43628-43635.
114. von Coelln R., et al. Parkin-associated Parkinson's disease. Cell Tissue Res. 2004, 318:175-184.
115. Bhandari P., et al. Mitochondrial contagion induced by parkin deficiency in Drosophila hearts and its containment by suppressing mitofusin. Circ. Res. 2013, 10.1161/CIRCRESAHA.114.302734.
116. Wenzel D.M., et al. UBCH7 reactivity profile reveals parkin and HHARI to be RING/HECT hybrids. Nature 2011, 474:105-108.